Tenax Therapeutics, Inc. (TENX) Stock Forecast
Data as of Aug 6, 2026Healthcare · Current price $13.34 (+2.22%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
TENX vs Sector & Market
| Metric | TENX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 7 | 8 | 18 |
| Target Upside | +136.8% | +16316.0% | +17.2% |
| P/E Ratio | -10.89 | 3.22 | 35.79 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4M | $4M | $4M | 6 |
| 2027-12-31 | $13M | $13M | $13M | 6 |
| 2028-12-31 | $47M | $47M | $47M | 6 |
| 2029-12-31 | $144M | $144M | $144M | 5 |
| 2030-12-31 | $296M | $296M | $296M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-4.53 | $-1.56 | $-0.83 | 6 |
| 2027-12-31 | $-3.44 | $-1.46 | $-0.70 | 4 |
| 2028-12-31 | $-1.83 | $-1.07 | $1.57 | 5 |
| 2029-12-31 | $-1.02 | $-1.02 | $-1.02 | 1 |
| 2030-12-31 | $0.19 | $0.19 | $0.19 | 1 |
Frequently Asked Questions
What is the analyst consensus for TENX?
The consensus among 7 analysts covering Tenax Therapeutics, Inc. (TENX) is Buy with an average price target of $25.00.
What is the highest price target for TENX?
The highest analyst price target for TENX is $25.00.
What is the lowest price target for TENX?
The lowest analyst price target for TENX is $25.00.
How many analysts cover TENX?
7 analysts have issued ratings for Tenax Therapeutics, Inc. in the past 12 months.
Is TENX a buy or sell right now?
Based on 7 analyst ratings, TENX has a consensus rating of Buy (2.00/5) with a +136.8% upside to the consensus target of $25.00.
What are the earnings estimates for TENX?
Analysts estimate TENX will report EPS of $-1.56 for the period ending 2026-12-31, with revenue estimated at $4M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.